Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy

[1]  L. Mezquita,et al.  Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer. , 2022, The Lancet. Oncology.

[2]  Robert W. Hsieh,et al.  Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. , 2022, The Lancet. Oncology.

[3]  F. Tanaka,et al.  CD155 expression and its clinical significance in non-small cell lung cancer , 2022, Oncology letters.

[4]  T. Barth,et al.  Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma , 2021, Neoplasia.

[5]  A. Tafreshi,et al.  Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Pircher,et al.  ASCO 2020 non-small lung cancer (NSCLC) personal highlights , 2021, memo - Magazine of European Medical Oncology.

[7]  D. Hwang,et al.  Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma , 2021, Scientific Reports.

[8]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[9]  Yi-long Wu,et al.  Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  D. Hwang,et al.  Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade. , 2020, JCI insight.

[11]  F. Tanaka,et al.  Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer , 2019, British Journal of Cancer.

[12]  R. Boidot,et al.  Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination , 2019, Journal of Immunotherapy for Cancer.

[13]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[14]  L. Schwartz,et al.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) , 2018, Journal of Immunotherapy for Cancer.

[15]  R. Sun,et al.  Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.

[16]  F. Tanaka,et al.  Prognostic impact of programmed death‐ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung , 2018, The Journal of thoracic and cardiovascular surgery.

[17]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[18]  J. Seong,et al.  Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model , 2017, Oncotarget.

[19]  K. Schalper,et al.  Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. , 2016, Cancer research.

[20]  T. Mitsudomi,et al.  Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). , 2016, Lung cancer.

[21]  B. Cho,et al.  Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. , 2016, Lung cancer.

[22]  Yiping Zhang,et al.  Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma , 2016, Journal of Translational Medicine.

[23]  G. Freeman,et al.  Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. , 2016, JCI insight.

[24]  Jingting Jiang,et al.  PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations , 2016, Cancer biology & therapy.

[25]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[26]  E. Wardelmann,et al.  PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups , 2015, PloS one.

[27]  Joe-Marc Chauvin,et al.  TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. , 2015, The Journal of clinical investigation.

[28]  Sean S. Park,et al.  PD-1 Restrains Radiotherapy-Induced Abscopal Effect , 2015, Cancer Immunology Research.

[29]  J. Hackney,et al.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.

[30]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[31]  Yih-Leong Chang,et al.  Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. , 2014, European journal of cancer.

[32]  Haiquan Chen,et al.  Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma , 2014, OncoTargets and therapy.

[33]  R. Johnstone,et al.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. , 2012, Cancer research.

[34]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Govindan,et al.  Locally advanced non-small cell lung cancer: the past, present, and future. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[37]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[38]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.